STOCKHOLM, May 31, 2023 /PRNewswire/ InDex Pharmaceuticals Holding AB (publ) ("InDex") today announced that a license agreement has been signed with Viatris Pharmaceutical Japan Inc. ("Viatris
May 31, 2023 - InDex Pharmaceuticals Holding AB today announced that a license agreement has been signed with Viatris Pharmaceutical Japan Inc. to register and commercialize cobitolimod in Japan. | June 7, 2023
/PRNewswire/ InDex Pharmaceuticals Holding AB (publ) today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE.
/PRNewswire/ InDex Pharmaceuticals Holding AB (publ) today announced that the Board of Directors has named Jenny Sundqvist as new CEO. Jenny comes from a.
/PRNewswire/ InDex Pharmaceuticals Holding AB (publ) today announced that the company has received positive feedback from the Japanese regulatory authority,.